Cancer Care Ontario | Cancer Care Ontario

282 Results

Guidelines and Advice

Follow-up Care, Surveillance Protocols and Secondary Prevention Measures for Survivors of Colorectal Cancer

Status: Current
ID: GL 26-2
Version: 3

Mar 2021

Guidelines and Advice

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Status: Current
ID: GL 27-2
Version: 2

Feb 2021

Guidelines and Advice

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Status: Education and Information
ID: 2-12
Version: 2

Oct 2013

Guidelines and Advice

Organizational Guideline for Gynecologic Oncology Services in Ontario

Status: In-Review
ID: 4-11

Jun 2013

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

Routine Human Papilloma Virus (HPV) Testing in Squamous Cell Head and Neck Cancer

Status: Current
ID: 5-9
Version: 2

Jan 2020

Guidelines and Advice

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Status: Education and Information
ID: 6-7 Version 2
Version: 2

Jun 2013

Guidelines and Advice

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Status: Education and Information
ID: 7-12 Version 2
Version: 2

May 2013

Guidelines and Advice

Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes

Status: Current
ID: GL #4-4v2
Version: 2

Sep 2020

Guidelines and Advice

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

Status: Archived
ID: MOAC 1

Nov 2013

Guidelines and Advice

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

Status: Current
ID: SCT 5

Aug 2013

Guidelines and Advice

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July 2011 to June 2012

Status: Current
ID: PET 2012-1

Sep 2013

Follow-up Care, Surveillance Protocols and Secondary Prevention Measures for Survivors of Colorectal Cancer

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Organizational Guideline for Gynecologic Oncology Services in Ontario

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Routine Human Papilloma Virus (HPV) Testing in Squamous Cell Head and Neck Cancer

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July 2011 to June 2012

Pages